Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended December 31, 1996, for Corniche Group Incorporated (CGI). The filing metadata references "Lisata Therapeutics," but the document content explicitly identifies the registrant as Corniche Group Incorporated. CGI has been inactive since February 1996, following the appointment of receivers to its UK operating subsidiaries (Chessbourne International Limited and The Stationery Company Limited) due to insolvency. The company's primary focus during the reporting period was settling outstanding liabilities and seeking interim financing to facilitate a potential acquisition.
Key Financial Metrics
| Metric | 9 Months Ended Dec 31, 1996 | 9 Months Ended Dec 31, 1995 |
|---|---|---|
| Net Sales | $0 | $0 |
| Operating Loss | $(112,663) | $(356,115) |
| Net Loss from Continuing Operations | $(167,915) | $(397,783) |
| Net Income (Loss) (Including Discontinued Ops) | $(167,915) | $1,636,821 |
| Cash at Period End | $10,055 | $210 |
| Total Assets | $10,899 | $136,201 (Mar 31, 1996) |
| Total Current Liabilities | $497,919 | $455,306 (Mar 31, 1996) |
| Stockholders' Deficiency | $(487,020) | $(319,105) (Mar 31, 1996) |
Liquidity and Debt: The company holds minimal cash ($10,055) against significant current liabilities ($497,919). Current liabilities include $105,000 in Notes Payable, $77,630 in debt compromise notes, and $132,485 in preferred dividends payable. The company is delinquent on federal and state tax filings for fiscal years 1994, 1995, and 1996.
Material Changes vs. Prior Period
- Operational Status: The company transitioned from active operations to a shell company status following the receivership of its UK subsidiaries in February 1996. Consequently, Net Sales are $0 for the current period.
- Expense Reduction: Selling, General, and Administrative (SG&A) expenses decreased significantly to $112,663 for the nine months ended Dec 31, 1996, compared to $356,115 in the prior year. This reduction is attributed to the cessation of operations and lower insurance and professional fees.
- Asset Liquidation: Total assets dropped from $136,201 (March 31, 1996) to $10,899 (December 31, 1996). This reflects the removal of UK subsidiary assets from the balance sheet and the collection of $125,000 on a previously outstanding note receivable.
- Financing Activity: The company raised $100,000 in gross proceeds during the quarter through a private offering of 4 units (notes and warrants), compared to $794,336 in stock issuance in the prior year.
Outlook, Risks, and Management Commentary
Going Concern: Management explicitly states that the company's ability to continue as a going concern is dependent on obtaining outside financing to support operations pending a suitable acquisition. There is no assurance that such financing or an acquisition will be completed.
Capital Raising: A private offering of securities (Rule 506) was terminated in December 1996 after raising $100,000. A subsequent offering commenced in January 1997, selling 17 units for a total of $425,000 (17 units x $25,000) as of April 30, 1997.
Risks and Contingencies:
- Legal Proceedings: The company settled class action securities complaints in 1994, paying $2.56 million in cash and issuing $1 million in preferred stock. A derivative action against former officers was dismissed in 1995. A lawsuit against former CEO Efriam Landa was settled in December 1996 via mutual release.
- Debt Settlement: A $77,630 note payable to the Bank of Scotland (debt compromise) was paid in full in January 1997, resulting in a mutual release of liabilities.
- Tax Compliance: The company is delinquent in filing income tax returns for multiple fiscal years.
Investor Verification Checklist
- Verify the current status of the private securities offering initiated in January 1997 and the total capital raised.
- Confirm the resolution of delinquent federal and state tax filings for fiscal years 1994–1996.
- Assess the company's progress in identifying and closing a suitable acquisition to restore operating status.
- Review the terms of the preferred stock dividend arrears ($132,485) and any potential conversion or settlement agreements.
- Validate the "Lisata Therapeutics" metadata reference against the actual registrant name (Corniche Group Incorporated) to ensure correct entity tracking.